These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35475881)

  • 1. CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain.
    Cho J; Yoon SE; Kim SJ; Ko YH; Kim WS
    Blood Adv; 2022 Dec; 6(24):6120-6130. PubMed ID: 35475881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
    Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T
    Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc/CD47 axis.
    Ren S; Cai Y; Hu S; Liu J; Zhao Y; Ding M; Chen X; Zhan L; Zhou X; Wang X
    Biochem Pharmacol; 2021 Jun; 188():114576. PubMed ID: 33930347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma.
    Kazama R; Miyoshi H; Takeuchi M; Miyawaki K; Nakashima K; Yoshida N; Kawamoto K; Yanagida E; Yamada K; Umeno T; Suzuki T; Kato K; Takizawa J; Seto M; Akashi K; Ohshima K
    Cancer Sci; 2020 Jul; 111(7):2608-2619. PubMed ID: 32342603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of CD68, cyclin D1 and rearrangement of bcl-6 gene are adverse prognostic factors in diffuse large B-cell lymphoma].
    Liang X; Wang J; Bai W; Sun R
    Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):559-64. PubMed ID: 26705179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffuse large B-cell lymphoma.
    Li S; Young KH; Medeiros LJ
    Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
    Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
    Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL).
    Zhang W; Fan Y; Li M; Yang L; Zhang Z; Liu L
    Dis Markers; 2021; 2021():4894022. PubMed ID: 34567285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunohistochemical classification and prognosis of diffuse large B-cell lymphoma in China].
    Chen Y; Xiao L; Zhu X; Lu C; Yu B; Fan D; Yin Y
    Zhonghua Bing Li Xue Za Zhi; 2014 Jun; 43(6):383-8. PubMed ID: 25208988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
    Bedekovics T; Hussain S; Feldman AL; Galardy PJ
    Blood; 2016 Mar; 127(12):1564-74. PubMed ID: 26702068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center.
    Li X; Xu-Monette ZY; Yi S; Dabaja BS; Manyam GC; Westin J; Fowler N; Miranda RN; Zhang M; Ferry JA; Medeiros LJ; Harris NL; Young KH
    Am J Surg Pathol; 2017 Oct; 41(10):1309-1321. PubMed ID: 28817403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
    Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
    J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of different protein expression levels in peripheral blood circulating tumor cells from patients with diffuse large B-cell lymphoma and their predictive efficiency for recurrence].
    Wang C; Zhou X; Liu GY; Qu CY; Yuan CY; Zhang YX
    Zhonghua Yi Xue Za Zhi; 2023 May; 103(17):1328-1333. PubMed ID: 37150683
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.
    Zhang YA; Yang X; Yao J; Ren Y; Liu P
    Dis Markers; 2022; 2022():3276925. PubMed ID: 35774848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
    Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
    J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
    Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
    Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
    Cendrowicz E; Jacob L; Greenwald S; Tamir A; Pecker I; Tabakman R; Ghantous L; Tamir L; Kahn R; Avichzer J; Aronin A; Amsili S; Zorde-Khvalevsky E; Gozlan Y; Vlaming M; Huls G; van Meerten T; Dranitzki ME; Foley-Comer A; Pereg Y; Peled A; Chajut A; Bremer E
    J Exp Clin Cancer Res; 2022 Mar; 41(1):97. PubMed ID: 35287686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
    Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
    J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR4 and CCR7 Expression in Primary Nodal Diffuse Large B-Cell Lymphoma-A Clinical and Immunohistochemical Study.
    Du H; Zhang L; Li G; Liu W; Tang W; Zhang H; Luan J; Gao L; Wang X
    Am J Med Sci; 2019 Apr; 357(4):302-310. PubMed ID: 30904045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL.
    Xu-Monette ZY; Zhang H; Zhu F; Tzankov A; Bhagat G; Visco C; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Hagemeister FB; Shahbaba B; De Dios I; Zhang H; Li Y; Xu B; Albitar M; Young KH
    Blood Adv; 2020 Jul; 4(14):3391-3404. PubMed ID: 32722783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.